Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OX2 Therapeutics Receives FDA Approval for Phase I Clinical Trial to Treat High-Grade Glioblastoma with Novel Peptide Checkpoint Inhibitor (CD200AR-L); First-of-Its Kind Peptide Also Being Developed As Platform for Possible Treatment of Other Solid Tumors.OX2 Therapeutics is a healthcare therapeutics company that focuses on treating brain tumors

List your booth number for exhibitions, ask us